Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Schulz H, Engert A, Diehl V, Schnell R, Borchmann P, Rüdiger T, Driessen C, Elter T, Morschhauser F, Rehwald U, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109-11.
01.01.2008
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
01.01.2008
Blood 2008; 111:109-11
Schulz Holger, Engert Andreas, Diehl Volker, Schnell Roland, Borchmann Peter, Rüdiger Thomas, Driessen Christoph, Elter Thomas, Morschhauser Franck, Rehwald Ute, Reiser Marcel
Weiter